Dr Reddy’s Q2 profit falls 36%, plans semaglutide relaunch in November

Mint - Oct 23, 2026

Lower US sales of generic Revlimid dragged down second-quarter earnings, but double-digit growth in base markets and the upcoming relaunch of semaglutide offer near-term relief.

Read full article

More News

Central News Today

Central News Today breaks down complex issues with unique perspective, bringing high-quality journalism to millions of readers around the world.

NEWSLETTER